[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bacterial-pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bacterial-pneumonia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100590351","a-post-marketing-study-to-assess-the-efficacy-and-safety-of-intravenous-polymyxin-b-and-colistin-methanesulfonate-in-patients-with-carbapenem-resistant-gram-negative-bacterial-infection-100590351",false,"NCT06966284","A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection","A Retrospective, Observational, Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Infusions Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection","Inclusion Criteria:\n\n1. Patient ≥ 18 years of age.\n2. Patient diagnosed with bacterial pneumonia and\u002For bacteremia, or other physician judged serious infection (except urinary tract infection, UTI) caused by Carbapenem-Resistant Gram-Negative Bacteria (CR-GNB).\n\n   CR-GNB: Resistant to at least one of the carbapenem antibiotics or produce a carbapenemase (an enzyme that can make them resistant to carbapenem antibiotics).\n\n   Diagnosis Criteria of HABP\u002FVABP:\n\n   • Met the clinical diagnosis criteria for HABP\u002FVABP. HABP: Acute bacterial pneumonia in a subject hospitalized for more than 48 hours or developing within 7 days after discharge from a hospital. Subject could have experienced acute respiratory failure and required mechanical ventilation for HABP.\n\n   VABP: Acute bacterial pneumonia in a subject receiving mechanical ventilation via an endotracheal (or nasotracheal) tube for a minimum of 48 hours.\n   * ≥ 1 of the following clinical features: new onset or worsening of pulmonary symptoms or signs, hypoxemia, need for acute changes in the ventilator support system to enhance oxygenation, new onset of or increase in suctioned respiratory secretions.\n   * ≥ 1 of the following signs: documented fever, hypothermia, WBC ≥ 10,000 cells\u002Fmm3, WBC ≤ 4500 cells\u002Fmm3, \\>15% immature neutrophils(bands)\n   * CXR or lung CT: presence of new or progressive infiltrates suggestive of bacterial pneumonia.\n\n   Diagnosis Criteria of BSI\u002FBacteremia: the BSI\u002Fsepsis category included bacteremia or sepsis caused by infections other than HABP\u002FVABP, or UTI:\n   * Documented BSI caused by a carbapenem-resistant Gram-negative pathogen; or\n   * Systemic response to infection, meeting the clinical criteria of SIRS and an identified infection source (eg, severe skin infection, intra-abdominal infection) caused by a carbapenem-resistant Gram-negative pathogen.\n3. Patient received intravenous polymyxin B or CMS treatment for ≥72 h.\n4. Administration of polymyxin B or CMS within 7 days from the infection onset day.\n\nInfection onset day: The date of specimen collection for index pathogen.\n\nExclusion Criteria:\n\n1. Patient with bacteremia caused by urinary tract infection.\n2. CR-GNB known to be resistant to polymyxin B or CMS.\n3. Patient has infectious disease (s) caused by the following gram-negative bacteria which are known to have no response to polymyxin B and\u002For colistin treatment: Proteus spp., Providencia spp., Morganella spp., Serratia marcescens, Burkholderia spp., and Neisseria spp.\n4. Intravenous administration of polymyxin B or colistin more than 28 days.\n5. Both the treatment efficacy and safety could not be evaluated.","ALL","18 Years",{"count":19,"type":20},480,"ESTIMATED","OBSERVATIONAL","This is a retrospective, observational, post-marketing study to evaluate the clinical response, microbiological response, mortality, and safety of intravenous polymyxin B and colistin methanesulfonate in patients with carbapenem-resistant gram-negative bacterial infection. Subgroup analysis by sites of infection, infectious pathogens, and baseline renal function will also be performed.",[24,25],"Bacteremia Caused by Gram-Negative Bacteria","Bacterial Pneumonia",[27],"polymyxin B sulfate","RECRUITING","2026-03-05",{"date":31,"type":32},"2026-03-09","ACTUAL",{"date":34,"type":32},"2025-11-26",{"date":36,"type":20},"2028-11-30",{"name":38,"class":39},"TTY Biopharm","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100622691","investigation-of-the-effects-of-oxidized-antigens-on-the-t-cell-response-and-the-epigenetic-reprogramming-of-neutrophils-in-lung-diseases---oxigene---100622691","NCT07386912","Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -","OXIGENE","Inclusion Criteria:\n\n* Diagnosis of an acute or chronic inflammatory lung disease, infectious or non-infectious, including asthma, COPD, pneumonia, tuberculosis, or viral pulmonary infection (e.g., COVID-19, influenza).\n* Age ≥ 18 years at the time of informed consent.\n* Ability to provide informed consent and consent to the collection and processing of clinical and laboratory data, as well as to the analysis of blood samples as part of study participation.\n* Sufficient physical condition to undergo a single venous blood draw (approximately 50 mL), as assessed by the treating physician.\n\nExclusion Criteria:\n\n* Active malignant disease or ongoing cancer therapy (e.g., chemotherapy or immunotherapy), due to potential immunological confounding.\n* Immunosuppressive therapy or known severe immunodeficiency that could interfere with the interpretation of cellular immune responses.\n* Pregnancy or breastfeeding, for general research-ethical reasons and to protect vulnerable populations.\n* Acute unstable clinical condition that, in the opinion of the treating physician, makes study participation unreasonable.\n* Known intolerance to blood sampling or relevant hematological disorders that could compromise the safety or feasibility of venipuncture.\n* Lack of capacity to provide informed consent or insufficient understanding of the study content despite supportive explanation.",{"count":49,"type":20},100,"The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections. By analyzing a single blood sample, the study examines how certain immune cells react during inflammation and infection, and whether lasting changes in these cells influence how strongly the body responds to disease. Although participants do not receive direct medical benefit, the results may help improve future diagnosis and treatment of lung diseases by providing deeper insight into immune responses.",[52,53,25,54,55],"Asthma","COPD","Viral Pneumonia","Tuberculosis",[57,58,59,60],"neutrophil granulocytes","epigenome","oxidation","antigens","NOT_YET_RECRUITING","2026-01-27",{"date":64,"type":32},"2026-02-04",{"date":66,"type":20},"2026-02-01",{"date":68,"type":20},"2030-12",{"name":70,"class":71},"Research Center Borstel","OTHER",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":72},"100577884","phase-4-efficacy-and-safety-of-faropenem-in-bangladeshi-adult-patients-with-community-acquired-bacterial-pneumonia-cabp-100577884","NCT06804096","Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)","Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP): A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male or female patients aged between 18 to 65 years.\n* Have an acute illness (less than or equal to 7 days duration) with any of the following signs and symptoms consistent with a lower respiratory tract infection (new or worsening):\n\n  1. Fever (body temperature \\> 38.0 °C (100.4 °F) measured orally)\n  2. Shortness of breath\n  3. New onset or increased cough with or without sputum production.\n  4. Chest pain.\n* Have radiographically documented bacterial pneumonia:\n\n  1. Infiltrates in a unilateral, lobar distribution\n  2. Diffuse opacities or white condensed area\n  3. The alveoli fill with white inflammatory fluid\n\nExclusion Criteria:\n\n* Patients with severe pneumonia (Clinical \\& Radiological Assessment)\n* Patients with suspicion of viral pneumonia (bilateral, patchy opacities, etc., in chest radiography.)\n* Patients with suspicion of nosocomial pneumonia, aspiration pneumonia, etc.\n* History of hypersensitivity, known or suspected contraindications, or intolerance to any of the study drugs.\n* Intake of an antibiotic within the last 48 hours before study admission.\n* History of hospitalization within the last 28 days.\n* Patients in pregnancy and lactational state.\n* Patients with Renal impairment (screening eGFR \\\u003C 30mL\u002Fmin).\n* Significant hepatic impairment (Alanine aminotransferase \\> three times the upper limit of normal).\n* Serious diseases that affect the immune system, such as Acquired Immunodeficiency Syndrome (AIDS), cancer, etc.\n* Patients who are taking steroid medications, at least 20 mg daily dose of prednisolone (or equivalent doses of other glucocorticoids).\n* Patients who are accepting chemotherapy or anti-cancer therapy or plan to receive such treatment during the trial or six months prior to enrollment.\n* Had epilepsy, stroke, or other central nervous system disorders or uncontrolled psychiatric history.","65 Years",{"count":82,"type":20},160,"INTERVENTIONAL",[85],"PHASE4","The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.",[88,25],"Pneumonia, Community-Acquired",[90,91],"CABP","Faropenem","2025-07-09",{"date":94,"type":32},"2025-07-11",{"date":96,"type":32},"2025-02-20",{"date":98,"type":20},"2025-12-01",{"name":100,"class":39},"Dr. Md. Alimur Reza"]